Comparative Pharmacology
Head-to-head clinical analysis: E Z PREP versus E Z EM PREP LYTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E Z PREP versus E Z EM PREP LYTE.
E-Z PREP vs E-Z-EM PREP LYTE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
E-Z Prep is a barium sulfate suspension used as a contrast agent for radiographic imaging. It does not have a pharmacodynamic mechanism of action; rather, it acts as a positive contrast medium by attenuating X-rays due to the high atomic number of barium, thereby enhancing visualization of the gastrointestinal tract.
Polyethylene glycol (PEG) 3350 is an osmotic laxative that induces diarrhea by retaining water in the bowel, thereby cleansing the colon. Electrolytes (sodium sulfate, sodium chloride, potassium chloride) are added to prevent electrolyte imbalance.
Radiographic examination of the esophagus, stomach, and duodenum (upper GI series)Radiographic examination of the small bowel (enteroclysis or small bowel follow-through)Computed tomography (CT) imaging of the gastrointestinal tract
Bowel cleansing prior to colonoscopyBowel preparation for barium enemaOff-label: Management of constipation
Oral: 45 mL (1.5 bottles) of 10% solution, followed by 45 mL (1.5 bottles) of 10% solution after 12 hours, for a total of 90 mL (3 bottles). Each dose is administered orally, typically mixed with water or juice.
Oral: 4 liters as a single dose for colonoscopy preparation.
None Documented
None Documented
Terminal elimination half-life is 16-24 hours; approximately 24 hours in elderly and patients with renal impairment, extending to >30 hours in severe renal disease.
The terminal elimination half-life of PEG 3350 is approximately 4-6 hours; clinical effects are largely non-systemic due to minimal absorption.
Barium sulfate is not metabolized and is excreted unchanged in the feces.
PEG 3350 is not significantly metabolized; it is excreted unchanged in feces. Electrolytes are absorbed or excreted via renal and gastrointestinal pathways.
Primarily renal excretion of unchanged drug (70-90%), with minor biliary/fecal elimination (10-20%).
Renal elimination of absorbed polyethylene glycol (PEG) is approximately 50-70% unchanged; the remainder is excreted in feces. Electrolytes are absorbed and renally excreted.
Approximately 27% bound to plasma proteins, primarily albumin.
PEG 3350: negligible protein binding (<1%); no specific binding proteins identified.
Volume of distribution is 0.1-0.2 L/kg, indicating limited distribution; primarily confined to extracellular fluid and gastrointestinal lumen.
Vd for PEG 3350 is approximately 0.2-0.3 L/kg; reflects distribution primarily in extracellular fluid with minimal tissue penetration.
Oral bioavailability is low (approximately 3-4%) due to poor absorption and extensive first-pass metabolism; minimal systemic absorption.
Oral bioavailability of PEG 3350 is approximately 10-20% due to minimal gastrointestinal absorption; electrolytes are absorbed systemically.
No formal dose adjustment is recommended for renal impairment; however, use with caution in patients with severe renal disease (GFR <30 mL/min) due to risk of phosphate overload or electrolyte imbalance. Consider alternative bowel preparations.
Contraindicated in patients with GFR < 30 mL/min; for GFR 30-60 mL/min, use with caution and ensure adequate hydration.
No dose adjustment required for hepatic impairment. However, use with caution in severe liver disease (Child-Pugh class C) due to potential for fluid retention or altered electrolyte balance.
No specific adjustment for Child-Pugh class A or B; for class C, use only if benefits outweigh risks due to potential for fluid overload.
Not recommended for use in pediatric patients. Safety and efficacy have not been established for individuals under 18 years of age.
Not indicated for patients under 18 years of age.
Use with caution in elderly patients due to increased risk of electrolyte abnormalities (e.g., hyperphosphatemia, hypernatremia) and dehydration. Dose adjustment is not required, but consider monitoring renal function and electrolytes before and after administration.
Use with caution due to increased risk of aspiration and electrolyte imbalance; consider split-dose regimen.
None
No FDA black box warning.
["Risk of aspiration: Avoid use in patients with suspected perforation of the GI tract, known or suspected obstruction, or severe dysphagia.","Hypersensitivity reactions: Rare cases of anaphylaxis may occur; observe for signs of allergic reaction.","Intravasation: Accidental intravenous administration can cause severe embolic events including cardiac arrest and death.","Constipation and impaction: Use with caution in patients with severe constipation, cystic fibrosis, or those undergoing bowel preparation.","Sodium load: Contains sodium; use with caution in patients with congestive heart failure or renal impairment."]
["Risk of electrolyte abnormalities (e.g., hypernatremia, hypokalemia) in patients with renal impairment or those taking diuretics","Aspiration risk, especially in patients with impaired gag reflex or swallowing disorders","Use caution in patients with colitis, toxic megacolon, or gastrointestinal obstruction","Potential for cardiac arrhythmias due to electrolyte shifts","Dehydration and fluid overload risk in elderly or debilitated patients"]
["Known or suspected gastrointestinal perforation","Known or suspected gastrointestinal obstruction","Hypersensitivity to barium sulfate or any component of the formulation","Severe dysphagia or risk of aspiration","Conditions where the use of a contrast agent is contraindicated (e.g., tracheoesophageal fistula)"]
["Gastrointestinal obstruction or perforation","Ileus or toxic megacolon","Severe renal impairment (e.g., creatinine clearance <30 mL/min)","Known hypersensitivity to any component","Active severe colitis"]
Data Pending Review
Data Pending Review
Avoid all solid foods during the bowel preparation period. Consume only clear liquids such as water, clear broth, tea, black coffee, and clear juices (apple, white grape). Avoid red, purple, or blue colored liquids. Dairy products, milk, and opaque liquids are not allowed.
Avoid all solid foods, milk, and red or purple liquids (e.g., grape juice, Jell-O) during preparation. Only clear liquids allowed: water, clear broth, apple juice, clear sodas, black coffee or tea (no milk), and clear gelatin (no fruit).
E-Z PREP (sodium phosphate monobasic monohydrate and sodium phosphate dibasic anhydrous) is a bowel evacuant. FDA Pregnancy Category C. Animal reproduction studies have not been conducted. It should be used during pregnancy only if clearly needed. Potential risks include electrolyte disturbances and dehydration in the mother, which could secondarily affect fetal well-being. No known teratogenic effects reported. Trimester-specific risks: unknown due to lack of data, but theoretical concerns for hypoperfusion in all trimesters.
E-Z-EM PREP LYTE is a balanced electrolyte solution (sodium sulfate, magnesium sulfate, potassium chloride) for colonoscopy preparation. There are no adequate and well-controlled studies in pregnant women. Animal studies are not available. The risk of electrolyte imbalance and dehydration may increase fetal risk if used improperly. In the first trimester, theoretical risks from electrolyte shifts; second and third trimesters, risk of maternal dehydration leading to reduced placental perfusion. Use only if clearly needed.
Systemic absorption is minimal after oral administration. Excretion into breast milk is expected to be negligible. The M/P ratio is not established. Caution is advised, especially in nursing infants with renal impairment. Consider use only if clearly needed.
No human data on excretion in breast milk. Electrolytes (sodium, potassium, magnesium) are normal milk constituents. M/P ratio unknown. While systemic absorption is minimal, consider risks of maternal dehydration or electrolyte imbalance. Use with caution in nursing mothers.
No specific dose adjustments recommended during pregnancy. However, increased plasma volume and glomerular filtration rate in pregnancy may alter pharmacokinetics. Use the lowest effective dose and ensure adequate hydration. Risk of hyperphosphatemia and hypocalcemia may be greater due to pregnancy-related changes. Dose should be individualized.
No specific dosing adjustments for pregnancy; standard dose (3 liters) may be used but with caution due to increased risk of dehydration and electrolyte disturbances. Consider reduced dose or split-dose in pregnant patients. Monitor closely.
Category C
Category C
E-Z PREP is a combination of sodium picosulfate, magnesium oxide, and citric acid used for bowel cleansing prior to colonoscopy. Ensure adequate hydration before, during, and after use. Monitor for electrolyte disturbances, especially in patients with renal impairment, heart failure, or those on diuretics. Split-dose regimen improves tolerability and efficacy. Avoid use in patients with gastrointestinal obstruction, toxic colitis, or megacolon.
E-Z-EM PREP LYTE is a polyethylene glycol (PEG)-based bowel preparation for colonoscopy. Ensure adequate hydration before, during, and after use to prevent electrolyte imbalance. Administer in divided doses per protocol. Monitor for nausea, bloating, or aspiration risk in elderly or debilitated patients. Contraindicated in GI obstruction, gastric retention, bowel perforation, toxic colitis, or megacolon.
Take E-Z PREP exactly as prescribed to achieve a clear bowel for colonoscopy.Follow a clear liquid diet for at least 24 hours before the procedure.Drink plenty of clear fluids to prevent dehydration.Expect diarrhea, bloating, and abdominal cramping; these are normal.Do not take within 2 hours of other medications; consult your doctor.
Do not eat solid food from the start of preparation until after the procedure. Consume only clear liquids.Mix the powder with water as directed and refrigerate for better taste. Do not add other flavors or sweeteners.Drink the entire amount over the prescribed time. For 4-liter preparation, drink 8 ounces every 10-15 minutes.Expect watery stools, which indicate effective cleansing. Stay near a restroom.If severe bloating, abdominal pain, vomiting, or inability to tolerate the solution occurs, contact your doctor.